Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Verve Therapeutics announces participation in the Guggenheim 2023 Genomic Medicines and Rare Disease Day on April 3, 2023. CEO Sekar Kathiresan will engage in a fireside chat at 10:45 a.m. ET, providing insights into the company's innovative approaches to cardiovascular disease treatment through gene editing.
The event will be available via a live webcast on the company’s website, archived for 30 days. Verve focuses on VERVE-101 and VERVE-201, targeting genes to lower LDL cholesterol, addressing conditions like familial hypercholesterolemia and atherosclerotic cardiovascular disease.
- None.
- None.
BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the Guggenheim 2023 Genomic Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:45 a.m. ET in NYC.
A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs – VERVE-101 and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with refractory hypercholesterolemia. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
When is Verve Therapeutics participating in the Guggenheim 2023 Genomic Medicines and Rare Disease Day?
Who is speaking at the Guggenheim 2023 Genomic Medicines and Rare Disease Day for Verve?
What is the focus of Verve Therapeutics' gene editing programs?
What are the main conditions targeted by Verve Therapeutics?
Where can I watch the webcast of Verve Therapeutics' presentation?
